Literature DB >> 8567901

Comparative evaluation of macrodilution and alamar colorimetric microdilution broth methods for antifungal susceptibility testing of yeast isolates.

W K To1, A W Fothergill, M G Rinaldi.   

Abstract

A comparative evaluation of the macrodilution method and the Alamar colorimetric method for the susceptibility testing of amphotericin B, fluconazole, and flucytosine was conducted with 134 pathogenic yeasts. The clinical isolates included 28 Candida albicans, 17 Candida tropicalis, 15 Candida parapsilosis, 12 Candida krusei, 10 Candida lusitaniae, 9 Candida guilliermondii, 18 Torulopsis glabrata, and 25 Cryptococcus neoformans isolates. The macrodilution method was performed and interpreted according to the recommendations of the National Committee for Clinical Laboratory Standards (document M27-P), and the Alamar colorimetric method was performed according to the manufacturer's instructions. For the Alamar colorimetric method, MICs were determined at 24 and 48 h of incubation for Candida species and T. glabrata and at 48 and 72 h of incubation for C. neoformans. The overall agreement within +/- 1 dilution for Candida species and T. glabrata against the three antifungal agents was generally good, with the values for amphotericin B, fluconazole, and flucytosine being 85.3, 77.9, and 86.2%, respectively, at the 24-h readings and 69.3, 65.2, and 97.2%, respectively, at the 48-h readings. Most disagreement was noted with fluconazole against C. tropicalis and T. glabrata. Our studies indicate that determination of MICs at 24 h by the Alamar colorimetric method is a valid alternate method for testing amphotericin B, fluconazole, and flucytosine against Candida species but not for testing fluconazole against C. tropicalis and T. glabrata. For flucytosine, much better agreement can be demonstrated against Candida species and T. glabrata at the 48-h readings by the Alamar method. Excellent agreement within +/- dilution can also be observed for amphotericin B, fluconazole, and flucytosine (80, 96, and 96%, respectively) against c. neoformans when the MICs were determined at 72 h by the Alamar method.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8567901      PMCID: PMC228550          DOI: 10.1128/jcm.33.10.2660-2664.1995

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  24 in total

1.  Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.

Authors:  A Espinel-Ingroff; C W Kish; T M Kerkering; R A Fromtling; K Bartizal; J N Galgiani; K Villareal; M A Pfaller; T Gerarden; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

2.  Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.

Authors:  J R Wingard; W G Merz; M G Rinaldi; T R Johnson; J E Karp; R Saral
Journal:  N Engl J Med       Date:  1991-10-31       Impact factor: 91.245

3.  Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii.

Authors:  J D Dick; B R Rosengard; W G Merz; R K Stuart; G M Hutchins; R Saral
Journal:  Ann Intern Med       Date:  1985-01       Impact factor: 25.391

4.  Hospital-acquired candidemia. The attributable mortality and excess length of stay.

Authors:  S B Wey; M Mori; M A Pfaller; R F Woolson; R P Wenzel
Journal:  Arch Intern Med       Date:  1988-12

5.  Fluconazole resistance in Candida glabrata.

Authors:  D W Warnock; J Burke; N J Cope; E M Johnson; N A von Fraunhofer; E W Williams
Journal:  Lancet       Date:  1988-12-03       Impact factor: 79.321

6.  Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing.

Authors:  A L Colombo; F Barchiesi; D A McGough; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

7.  Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System.

Authors:  S N Banerjee; T G Emori; D H Culver; R P Gaynes; W R Jarvis; T Horan; J R Edwards; J Tolson; T Henderson; W J Martone
Journal:  Am J Med       Date:  1991-09-16       Impact factor: 4.965

8.  Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts.

Authors:  R A Fromtling; J N Galgiani; M A Pfaller; A Espinel-Ingroff; K F Bartizal; M S Bartlett; B A Body; C Frey; G Hall; G D Roberts
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

9.  Susceptibility testing of Cryptococcus neoformans: a microdilution technique.

Authors:  M A Ghannoum; A S Ibrahim; Y Fu; M C Shafiq; J E Edwards; R S Criddle
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

10.  Comparison study of broth macrodilution and microdilution antifungal susceptibility tests.

Authors:  A Espinel-Ingroff; T M Kerkering; P R Goldson; S Shadomy
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

View more
  19 in total

1.  Comparative evaluation of PASCO and national committee for clinical laboratory standards M27-A broth microdilution methods for antifungal drug susceptibility testing of yeasts.

Authors:  B A Arthington-Skaggs; M Motley; D W Warnock; C J Morrison
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Fluorometric assessment of In vitro antidermatophytic activities of antimycotics based on their keratin-penetrating power.

Authors:  C N Okeke; R Tsuboi; M Kawai; H Ogawa
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Use of the sensititre colorimetric microdilution panel for antifungal susceptibility testing of dermatophytes.

Authors:  I Pujol; J Capilla; B Fernández-Torres; M Ortoneda; J Guarro
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

Review 4.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

5.  Trends in antifungal susceptibility among Swedish Candida species bloodstream isolates from 1994 to 1998: comparison of the E-test and the Sensititre YeastOne Colorimetric Antifungal Panel with the NCCLS M27-A reference method.

Authors:  E Chryssanthou
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

6.  Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.

Authors:  M A Pfaller; D J Diekema; M Mendez; C Kibbler; P Erzsebet; S-C Chang; D L Gibbs; V A Newell
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

7.  Novel fluorescent broth microdilution method for fluconazole susceptibility testing of Candida albicans.

Authors:  R S Liao; R P Rennie; J A Talbot
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

8.  Comparative evaluation of a new fluorescent carboxyfluorescein diacetate-modified microdilution method for antifungal susceptibility testing of Candida albicans isolates.

Authors:  Robert S Liao; Robert P Rennie; James A Talbot
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  Multicenter comparison of the sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms.

Authors:  A Espinel-Ingroff; M Pfaller; S A Messer; C C Knapp; S Killian; H A Norris; M A Ghannoum
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

10.  Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species.

Authors:  Joseph Meletiadis; Johan W Mouton; Jacques F G M Meis; Bianca A Bouman; Paul E Verweij
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.